Cost effectiveness of leukotriene modifiers in adults with asthma

PharmacoEconomics

Volumn 24, Issue 8, 2006, Pages 727-742

  Heaton, Pamela C ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPHYLLINE; ANTIINFLAMMATORY AGENT; ARACHIDONATE 5 LIPOXYGENASE; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID DERIVATIVE; CROMOGLYCATE DISODIUM; FLUTICASONE PROPIONATE; LEUKOTRIENE DERIVATIVE; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; METHYLXANTHINE DERIVATIVE; MONTELUKAST; SALMETEROL; SHORT ACTING DRUG; THEOPHYLLINE; ZAFIRLUKAST; ZILEUTON;

BASOPHIL; BRONCHOSPASM; CHRONIC DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DATA BASE; DISEASE SEVERITY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; ECONOMIC ASPECT; EOSINOPHIL; HUMAN; LIVER TOXICITY; MAST CELL; MEDICAL LITERATURE; META ANALYSIS; MILD PERSISTENT ASTHMA; NOSE SECRETION; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SYSTEMATIC REVIEW; THRUSH; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; LEUKOTRIENE ANTAGONISTS;

EID: 33747197438     PISSN: 11707690     EISSN: 11707690     Source Type: Journal    
DOI: 10.2165/00019053-200624080-00001     Document Type: Review

References (60)

1. Rochester C, Noble S. Choosing treatment options for patients with asthma. Drug Topics 1997; 141: 74-83
2. National Heart, Lung, and Blood Institute. Guidelines for the diagnosis and management of asthma. Bethesda (MD): National Heart, Lung, and Blood Institute, 1997 July. NIH publication no.: 97-4051
3. National Heart, Lung, and Blood Institute. Guidelines for the diagnosis and management of asthma: update on selected topics 2002. Bethesda (MD): National Heart, Lung, and Blood Institute; 2002 Jun. NIH publication no.: 02-5075
4. O'Byrne P. Global Initiative for Asthma. Global Initiative for Asthma guidelines [online]. Available from URL: http://www.ginasthma.com/Guidelineitem. asp??l1=2&l2=1&intId=37 [Accessed 2006 Apr]
5. Asthma prevalence, health care use and mortality, 2002. US Department of Health and Human Services. New asthma estimates: tracking prevalence, health care, and mortality [online]. Available from URL: http://www.cdc.gov/nchs/ products/pubs/pubd/hestats/asthma/asthma.htm [Accessed 2002 Jul 16]
6. Weiss KB, Sullivan SD. The health economics of asthma and rhinitis. I: assessing the economic impact. J Allergy Clin Immunol 2001; 107: 3-8
7. Pappas G, Hadden W, Kozak L, et al. Potentially avoidable hospitalizations: inequalities in rates between US socioeconomic groups. Am J Public Health 1997; 87: 811-6
8. National Heart, Lung, and Blood Institute. Global initiative for asthma. Bethesda (MD): NIH, 1995 Jul. pPublication no.: 95-3659
9. Podell R. National guidelines for the management of asthma in adults. Am Fam Physician 1992; 46: 1189-96
10. Doerschug KC, Peterson MW, Dayton CS, et al. Asthma guidelines: an assessment of physician understanding and practice. Am J Respir Crit Care Med 1999; 159: 1735-41
11. Critical Therapeutics. Home page [online]. Available from URL: http://www.criticaltherapeutics.com [Accessed 2006 Apr 25]
12. Fish JE, Kemp JP, Lockey RF, et al. Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group. Clin Ther 1997; 19: 675-90
13. Nathan RA, Bernstein JA, Bielory L, et al. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. J Allergy Clin Immunol 1998; 102: 935-42
14. Adkins JC, Brogden RN. Zafirlukast: a review of its pharmacology and therapeutic potential in the management of asthma. Drugs 1998; 55: 121-44
15. Suissa S, Dennis R, Ernst P, et al. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997; 126: 177-83
16. Edelman JM, Turpin JA, Bronsky EA, et al. Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction: a randomised, double-blind trial. Ann Int Med 2000; 132: 99-104
17. Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclometasone, and placebo for chronic asthma: a randomized, controlled trial. Montelukast/Beclometasone Study Group. Ann Intern Med 1999; 130: 487-95
18. Bleecker ER, Welch MJ, Weinstein SF, et al. Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. J Allergy Clin Immunol 2000; 105: 1123-9
19. Laviolette M, Malmstrom K, Lu S, et al. Montelukast added to inhaled beclometasone in treatment of asthma. Montelukast/Beclometasone Additivity Group. Am J Respir Crit Care Med 1999; 160: 1862-8
20. Fish JE, Israel E, Murray JJ, et al. Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest 2001; 120: 423-30
21. Kim KT, Ginchansky EJ, Friedman BF, et al. Fluticasone propionate versus zafirlukast: effect in patients previously receiving inhaled corticosteroid therapy. Ann Allergy Asthma Immunol 2000; 85: 398-406
22. Stempel DA, Pinto L, Stanford RH. The risk of hospitalization in patients with asthma switched from an inhaled corticosteroid to a leukotriene receptor antagonist. J Allergy Clin Immunol 2002; 110: 39-41
23. Lofdahl CG, Reiss TF, Leff JA, et al. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ 1999; 319: 87-90
24. Ducharme F, Schwartz Z, Hicks G, et al. Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev 2004; (2): CD003133
25. Busse W, Nelson H, Wolfe J, et al. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. J Allergy Clin Immunol 1999; 103: 1075-80
26. Ram F, Cates C, Ducharme F. Long-acting β2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev 2005; (1): CD003137
27. Sterk PJ, Buist SA, Woolcock AJ. The message from the world asthma meeting. Eur Respir J 1999; 14: 1435-53
28. Menendez R, Stanford RH, Edwards L, et al. Cost-efficacy analysis of fluticasone propionate versus zafirlukast in patients with persistent asthma. Pharmacoeconomics 2001; 19: 865-74
29. O'Connor RD, Nelson H, Borker R, et al. Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma. Pharmacoeconomics 2004; 22: 815-25
30. Sheth K, Borker R, Emmett A, et al. Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma. Pharmacoeconomics 2002; 20: 909-18
31. Armstrong EP, Malone DC. Fluticasone is associated with lower asthma-related costs than leukotriene modifiers in a real-world analysis. Pharmacotherapy 2002; 22: 1117-23
32. Bukstein DA, Henk HJ, Luskin AT. A comparison of asthma-related expenditures for patients started on montelukast versus fluticasone propionate as monotherapy. Clin Ther 2001; 23: 1589-600
33. Klingman D, Bielory L, Wang Y, et al. Asthma outcome changes associated with use of the leukotriene-receptor antagonist zafirlukast. Manag Care Interface 2001; 14: 62-6
34. O'Connor RD, O'Donnell JC, Pinto LA, et al. Two-year retrospective economic evaluation of three dual-controller therapies used in the treatment of asthma. Chest 2002; 121: 1028-35
35. O'Connor RD, Stanford R, Crim C, et al. Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs. Ann Allergy Asthma Immunol 2004; 93: 581-8
36. Orsini L, Limpa-Amara S, Crown WH, et al. Asthma hospitalization risk and costs for patients treated with fluticasone propionate vs montelukast. Ann Allergy Asthma Immunol 2004; 92: 523-9
37. Pathak DS, Davis EA, Stanford RH. Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population. Pharmacotherapy 2002; 22: 166-74
38. Price DB, Ben-Joseph RH, Zhang Q. Changes in asthma drug therapy costs for patients receiving chronic montelukast therapy in the UK. Respir Med 2001; 95: 83-9
39. Stempel DA, Mauskopf J, McLaughlin T, et al. Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast. Respir Med 2001; 95: 227-34
40. Stempel DA, Meyer JW, Stanford RH, et al. One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma. J Allergy Clin Immunol 2001; 107: 94-8
41. Stempel DA, O'Donnell JC, Meyer JW. Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs. J Allergy Clin Immunol 2002; 109: 433-9
42. Halpern MT, Khan ZM, Stanford RH, et al. Asthma: resource use and costs for inhaled corticosteroid vs leukotriene modifier treatment: a meta-analysis. J Fam Pract 2003; 52: 382-9
43. Hill SR, Mitchell AS, Henry DA. Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA 2000; 283: 2116-21
44. Snyder L, Blanc PD, Katz PP, et al. Leukotriene modifier use and asthma severity: how is a new medication being used by adults with asthma? Arch Intern Med 2004; 164: 617-22
45. Drazen JM, Boccuzzi SJ, Wogan J, et al. Adherence to prescribed treatment for asthma. Am J Respir Crit Care Med 2000 161: A402
46. Stoloff SW, Stempel DA, Meyer J, et al. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol 2004; 113: 245-51
47. Reinus JF, Persky S, Burkiewicz JS, et al. Severe liver injury after treatment with the leukotriene receptor antagonist zafirlukast. Ann Intern Med 2000; 133: 964-8
48. Wechsler ME, Pauwels R, Drazen JM. Leukotriene modifiers and Churg-Strauss syndrome: adverse effect or response to corticosteroid withdrawal? Drug Saf 1999; 21: 241-51
49. Sivri A, Coplu L. Effect of the long-term use of inhaled corticosteroids on bone mineral density in asthmatic women. Respirology 2001; 6: 131-4
50. Israel E, Banerjee TR, Fitzmaurice GM, et al. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med 2001; 345: 941-7
51. Tug T, Kamanli A, Tug E. Effects of long-term inhaled steroid use on bone mineral density in asthma patients. J Investig Allergol Clin Immunol 2001; 11: 300-2
52. Elmstahl S, Ekstrom H, Galvard H, et al. Is there an association between inhaled corticosteroids and bone density in postmenopausal women? J Allergy Clin Immunol 2003; 111: 91-6
53. Halpern MT, Schmier JK, Van Kerkhove MD, et al. Impact of long-term inhaled corticosteroid therapy on bone mineral density: results of a meta-analysis. Ann Allergy Asthma Immunol 2004; 92: 201-7
54. Stempel DA. Economic analysis of asthma practices. Am J Manag Care 2000; 6: S930-6
55. Hendeles L, Segal R. Pharmacoeconomic studies of asthma controller drugs: marketing gimmick or icing on the cake? Pharmacotherapy 2002; 22: 131-3
56. Chen Y, Dales R, Tang M, et al. Obesity may increase the incidence of asthma in women but not in men: longitudinal observations from the Canadian National Population Health Surveys. Am J Epidemiol 2002; 155: 198-202
57. Guerra S, Sherrill DL, Bobadilla A, et al. The relation of body mass index to asthma, chronic bronchitis, and emphysema. Chest 2002; 122: 1256-63
58. Shaheen SO, Sterne JA, Montgomery SM, et al. Birth weight, body mass index and asthma in young adults. Thorax 1999; 54: 396-402
59. Kuo A, Craig TJ. A retrospective study of risk factors for repeated admissions for asthma in a rural/suburban university hospital. J Am Osteopath Assoc 2001; 101 Suppl. 5: 14-7
60. Hessel PA, Mitchell I, Tough S, et al. Risk factors for death from asthma. Prairie Provinces Asthma Study Group. Ann Allergy Asthma Immunol 1999; 83: 362-8